Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  Feasibility and acceptance of simultaneous amyloid PET/MRI

Schütz, L., Lobsien, D., Fritzsch, D., Tiepolt, S., Werner, P., Schroeter, M. L., et al. (2016). Feasibility and acceptance of simultaneous amyloid PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 43(12), 2236-2243. doi:10.1007/s00259-016-3462-x.

Item is

Basisdaten

einblenden: ausblenden:
Genre: Zeitschriftenartikel

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Schütz, Lisa1, Autor
Lobsien, Donald2, Autor
Fritzsch, Dominik2, Autor
Tiepolt, Solveig1, Autor
Werner, Peter1, Autor
Schroeter, Matthias L.3, 4, 5, Autor           
Berrouschot, Jörg6, Autor
Saur, Dorothee7, Autor
Hesse, Swen1, 5, Autor
Jochimsen, Thies1, Autor
Rullmann, Michael1, Autor           
Sattler, Bernhard1, Autor
Patt, Marianne1, Autor
Gertz, Hermann-Josef8, Autor
Villringer, Arno3, 4, 5, Autor           
Claßen, Joseph7, Autor
Hoffmann, Karl-Titus2, Autor
Sabri, Osama1, 5, Autor
Barthel, Henryk1, Autor
Affiliations:
1Department of Nuclear Medicine, University of Leipzig, Germany, ou_persistent22              
2Department of Neuroradiology, University of Leipzig, Germany, ou_persistent22              
3Clinic for Cognitive Neurology, University of Leipzig, Germany, ou_persistent22              
4Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society, Leipzig, DE, ou_634549              
5Integrated Research and Treatment Center Adiposity Diseases, University of Leipzig, Germany, ou_persistent22              
6Clinical Centre Altenburger Land, Altenburg, Germany, ou_persistent22              
7Department of Neurology, University of Leipzig, Germany, ou_persistent22              
8Department of Psychiatry, University of Leipzig, Germany, ou_persistent22              

Inhalt

einblenden:
ausblenden:
Schlagwörter: PET/MRI; Amyloid; Alzheimer’s disease; MCI
 Zusammenfassung: Purpose

Established Alzheimer’s disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging (PET/MRI) offers the chance to obtain both biomarker category read-outs within one imaging session, with increased patient as well as referrer convenience. The aim of this pilot study was to investigate this matter for the first time.
Methods

100 subjects (age 70 ± 10 yrs, 46 female), n = 51 with clinically defined mild cognitive impairment (MCI), n = 44 with possible/probable AD dementia, and n = 5 with frontotemporal lobe degeneration, underwent simultaneous [18F]florbetaben or [11C]PIB PET/MRI (3 Tesla Siemens mMR). Brain amyloid load, mesial temporal lobe atrophy (MTLA) by means of the Scheltens scale, and other morphological brain pathologies were scored by respective experts. The patients/caregivers as well as the referrers were asked to assess on a five-point scale the convenience related to the one-stop-shop PET and MRI approach.
Results

In three subjects, MRI revealed temporal lobe abnormalities other than MTLA. According to the National Institute on Aging-Alzheimer’s Association classification, the combined amyloid-beta PET/MRI evaluation resulted in 31 %, 45 %, and 24 % of the MCI subjects being categorized as “MCI-unlikely due to AD”, “MCI due to AD-intermediate likelihood”, and “MCI due to AD-high likelihood”, respectively. 50 % of the probable AD dementia patients were categorized as “High level of evidence of AD pathophysiological process”, and 56 % of the possible AD dementia patients as “Possible AD dementia - with evidence of AD pathophysiological process”. With regard to the International Working Group 2 classification, 36 subjects had both positive diagnostic and progression biomarkers. The patient/caregiver survey revealed a gain of convenience in 88 % of responders as compared to a theoretically separate PET and MR imaging. In the referrer survey, an influence of the combined amyloid-beta PET/MRI on the final diagnosis was reported by 82 % of responders, with a referrer acceptance score of 3.7 ± 1.0 on a 5-point scale.
Conclusion

Simultaneous amyloid PET/MRI is feasible and provides imaging biomarkers of all categories which are able to supplement the clinical diagnosis of MCI due to AD and that of AD dementia. Further, patient and referrer convenience is improved by this one-stop-shop imaging approach.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2016-05-132016-07-062016-07-192016-11
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: Expertenbegutachtung
 Identifikatoren: DOI: 10.1007/s00259-016-3462-x
PMID: 27435367
Anderer: Epub 2016
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: European Journal of Nuclear Medicine and Molecular Imaging
  Andere : Eur. J. Nucl. Med. Mol. Imaging
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Heidelberg, Germany : Springer
Seiten: - Band / Heft: 43 (12) Artikelnummer: - Start- / Endseite: 2236 - 2243 Identifikator: ISSN: 1619-7070
CoNE: https://pure.mpg.de/cone/journals/resource/954925519624